AI assistant
Sending…
Pluri Inc. — Director's Dealing 2025
Nov 13, 2025
6990_rns_2025-11-13_12b14ad8-82d8-4e0d-9191-765c6928a23c.htm
Director's Dealing
Open in viewerOpens in your device viewer
{# SEO P0-1: filing HTML is rendered server-side so Googlebot
sees the full text without executing JS or following an
iframe to a Disallow'd CDN path. The content has already
been sanitized through filings.seo.sanitize_filing_html. #}
_________ false
| פלורי אינק | 2 381 |
| PLURI INC | |
| Corporation no: C12337-2001 | 15574 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C003 ( Public ) | Reported via MAGNA: | 13/11/2025 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2025-02-087122 | Time of broadcast: 15:49 15:49 |
Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
| Attached hereto is a report on | FORM 4 - שינוי החזקות ב"ע/נ.משרה - Eitan Ajchenbaum |
ea026550301-4ajchenbaum_pluriEDGAR1_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 06/08/2024 |
| Address: Matam Park 5 , Haifa 31905 ISRAEL , Tel: 074-7107171 , Fax: 074-7107172 | |
| E-mail address: [email protected] Company site: www.pluristem.com | |
| Previous names of reporting entity: PLURISTEM THERAPEUTICS INC | |
| Name of the Signatory: Zalts Zelig Liat Position of Signatory in the reporting corporation: CFO, Senior Vice president & Treasurer Name of Employer Company: | |
| Address: Matam Park 5 , Haifa 3190500 Telephone: 074-7108600 Facsimile: E-mail: [email protected] 1 | |
More from Pluri Inc.
Report Publication Announcement
2026
Apr 24
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Report Publication Announcement
2026
Mar 27
Capital/Financing Update
2026
Mar 27
Regulatory Filings
2026
Mar 27
Share Issue/Capital Change
2026
Mar 26